West Pharmaceutical releases 2021 Corporate Responsibility Report; highlights include 85% of global waste diverted from landfills, water and energy intensity ratios improved from prior year, 64% of executive team made up of women and/or minorities

Sample article from our Health Care Sector

July 26, 2022 (press release) –

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has recently released its 2021 Corporate Responsibility Report, reporting on the Company's environmental, social, and governance (ESG) performance in 2021.

This is West's 6th annual CR Report, and highlights ESG successes from over the past year, including progress on environmental sustainability goals, diversity and inclusion, and success around the Company's philanthropic efforts.  It also highlights some of the recognition received for its ESG performance, including placement in Barron's Top 100 Most Sustainable Companies, Corporate Social Responsibility Programme of the Year from Pharma Industry Awards in Ireland, and a Silver Stevie Award for Corporate Social Responsibility.

"At West, we are driven by our purpose to improve patient lives. We know that to fulfill this purpose effectively, we must consider our broader corporate responsibilities to the wide range of stakeholders we serve," said Eric M. Green, President, Chief Executive Officer and Chair of the Board.  "Much of our long-term success can be credited to our focus on building a diverse team, putting quality at center stage, operating with integrity, giving back to our communities, managing our environmental footprint, and caring for the health and safety of our team members – all of these combined makes for a better performing company now and into the future."

Some of the key 2021 highlights include:

  • ESG Governance changes, including the establishment of an ESG Steering Committee, new areas of priority focus for the future and additional oversight by West's Board of Directors
  • Global waste to landfill for all West manufacturing sites continued to improve, with 85% of global waste diverted from landfill, up from 77% the prior year
  • Both water and energy intensity ratios improved over prior year, meaning less energy and water is being used for each product produced
  • 64% of West's Executive Team is made up of women and/or U.S. minorities
  • 7 of West's manufacturing sites had zero recordable safety incidents in 2021
  • Total employee giving increased by 72% from 2020
  • Team member donations to West's Annual Global Food Drive increased by 56% over prior year

In addition to the CR Report, West also provides transparency in disclosure through alignment with the United Nations Sustainable Development Goals, the Sustainability Accounting Standards Board (SASB) Index, and the Task Force on Climate-Related Financial Disclosures (TCFD).

Please read the full CR Report here to learn more about West's commitment to ESG.

About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year. 

Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

SOURCE West Pharmaceutical Services, Inc.

Media Contact: Eric Haman, Director, Global Corporate Communications, +1-215-873-3772, Eric.Haman@westpharma.com or Investor Relations Contact: Quintin Lai, +1-610-594-3318, Quintin.Lai@westpharma.com

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.